Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
109,272,143
-
Total 13F shares
-
2,820,198
-
Share change
-
+1,321,437
-
Total reported value
-
$3,771,684
-
Price per share
-
$1.40
-
Number of holders
-
56
-
Value change
-
+$1,889,818
-
Number of buys
-
18
-
Number of sells
-
15
Institutional Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) as of Q3 2025
As of 30 Sep 2025,
ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,820,198 shares.
The largest 10 holders included
MORGAN STANLEY, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, SEEDS INVESTOR LLC, GOLDMAN SACHS GROUP INC, INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC, Quadrature Capital Ltd, FRANKLIN RESOURCES INC, ROYAL BANK OF CANADA, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
56
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.